Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2315)	3/1/2001 1:44:37 AM
From: scaram(o)uche	Read Replies (1) of 4974

>> Agouron had strong move because at the time there was nothing else to bet on it. Today we have different picture. Many bios entered race. << Agouron moved in response (and in proportion) to projected sales of Viracept. The same thing would happen if ICOS were to bring forward a successful PDE5 inhibitor tomorrow. It's easy to get depressed and suggest that market mood will hold an issue back in the face of good news. But, if the good news is a major clinical success, it just plain won't happen. If there are twenty major successes in the clinic, twenty stocks will kick up their heels.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next